RPCEC00000245招募中4 期
Evaluation of the safety and effectiveness of CIMAher® (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma of pancreas and unresectable or metastatic. Phase IV
Center of Molecular Immunology0 个研究点开始时间: 2017年4月30日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 one（—）
- 性别
- All
入选标准
- •1. Patients who meet the diagnostic criteria.
- •2. Patient who provides written consent to participate in the study.
- •3. Patient with age equal to or greater than 18 years.
- •4. Life expectancy equal to or greater than 3 months.
- •5. Clinical status according to criteria of ECOG equal to or greater than 2
- •6. Patients receiving treatment with QT.
- •7. Laboratory parameters within the limits established in the protocol.
排除标准
- •1. Patient pregnant, lactating or puerperal.
- •2. Patient with a second primary tumor.
- •3. Patient with chronic or uncontrolled intercurrent diseases (eg heart disease, diabetes, high blood pressure).
- •4. Patient with a history of hypersensitivity to any component of the formulation of Nimotuzumab or chemotherapy.
- •5. Patient who received Nimotuzumab or other biological therapy 6 months prior to enrollment or is receiving another research product.
- •6. Patient childbearing age who do not accept use appropriate contraceptive methods
研究者
相似试验
招募中
Unknown
Evaluation of the efficiency and safety of imeglimin on insulin secretion ability and insulin sensitivity in the treatment of type 2 diabetes mellitustype 2 diabetesJPRN-UMIN000053150Department of Diabetes and Metabolism,Tohto Clinic30
进行中（未招募）
1 期
An evaluation of the safety and effectiveness of combination therapy using the thiazolidinedione pioglitazone alongside insulin in type 2 diabetes mellitus.Type 2 Diabetes MellitusEUCTR2006-001982-41-GBBradford Teaching Hospitals NHS Foundation Trust40
招募中
不适用
Evaluation of safety and effectiveness regarding intraocular cyclophotocoagulation for refractory glaucomaRefractory terminal glaucoma Glaucoma absolutumJPRN-UMIN000027090Sato Yuya Eye Clinic20
尚未招募
Unknown
CAL(Cell assisted lipo-transfer) in treating recurrent complex anal fistulaKCT0008334Hangun Hospital Bumcheon Campus20
进行中（未招募）
1 期
Immune Therapy in Combination with Checkpoint Inhibitor Treatmentnresectable, Stage III or Stage IV metastatic melanoma who are either previously untreated (cohort A), or whose disease has progressed during PD-1 blockade (cohort B).MedDRA version: 21.1Level: PTClassification code 10028980Term: NeoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001346-34-GBImmodulon Therapeutics Ltd16